Increased Diagnostic Yield of Spastic Paraplegia with or Without Cerebellar Ataxia Through Whole-Genome Sequencing
Inherited disorders of spasticity or ataxia exist on a spectrum with overlapping causative genes and phenotypes. We investigated the use of whole-genome sequencing (WGS) to detect a genetic cause when considering this spectrum of disorders as a single group. We recruited 18 Korean individuals with spastic paraplegia with or without cerebellar ataxia in whom common causes of hereditary cerebellar ataxia and hereditary spastic paraplegia had been excluded. We performed WGS with analysis for single nucleotide variants, small insertions and deletions, copy number variants (CNVs), structural variants (SVs) and intronic variants. Disease-relevant variants were identified in ABCD1 (n = 3), CAPN1 (n = 2), NIPA1 (n = 1) and PLA2G6 (n = 1) for 7/18 patients (38.9%). A ‘reverse phenotyping’ approach was used to clarify the diagnosis in individuals with PLA2G6 and ABCD1 variants. One of the ABCD1 disease-relevant variants was detected on analysis for intronic variants. No CNV or SV causes were found. The two males with ABCD1 variants were initiated on monitoring for adrenal dysfunction. This is one of only a few studies to analyse spastic-ataxias as a continuous spectrum using a single approach. The outcome was improved diagnosis of unresolved cases for which common genetic causes had been excluded. This includes the detection of ABCD1 variants which had management implications. Therefore, WGS may be particularly relevant to diagnosing spastic ataxias given the large number of genes associated with this condition and the relatively high diagnostic yield.
KeywordsWhole-genome sequencing Spastic Ataxia Cerebellar Hereditary spastic paraplegia Diagnosis
DNA for this study was provided by the Seoul National University Hospital Human Biobank, a member of the National Biobank of Korea, which is supported by the Ministry of Health and Welfare. All samples derived from the National Biobank of Korea were obtained with informed consent under institutional review board-approved protocols. We would like to thank Dr. Sarah Kummerfeld, Garvan Institute of Medical Research, for reviewing the manuscript.
Whole-genome sequencing was funded by a University of Sydney Kickstarter Grant awarded to KRK. RLD and MJC are supported by Early-Mid Career New South Wales Health Fellowships. CMS is supported by a National Health and Medical Research Council Practitioner Fellowship.
Compliance with Ethical Standards
All patients provided written informed consent according to the Declaration of Helsinki. The objectives and procedures of the study were approved by the institutional review board (Seoul National University Hospital: reference number 1601-048-733).
Conflict of Interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
This article does not contain any studies with animals performed by any of the authors.
- 7.Minoche AE, Horvat C, Johnson R, Gayevskiy V, Morton SU, Drew AP, et al. Genome sequencing as a first-line genetic test in familial dilated cardiomyopathy. Genet Med. 2019;21:650-62.Google Scholar
- 21.Kopanos CTV, Kouris A, Chapple CE, Aguilera MA, Meyer R, Massouras A. VarSome: the human genomic variant search engine. Bioinformatics. 2018. https://doi.org/10.1093/bioinformatics/bty897 [Epub ahead of print]
- 22.Kirk EP, Barlow-Stewart K, Selvanathan A, Josephi-Taylor S, Worgan L, Rajagopalan S, et al. Beyond the panel: preconception screening in consanguineous couples using the TruSight one “clinical exome”. Genet Med. 2019;21:608-12.Google Scholar
- 23.Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.CrossRefGoogle Scholar
- 31.Raymond GV, Moser AB, Fatemi A. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. X-Linked Adrenoleukodystrophy. Seattle (WA): GeneReviews((R)); 1993.Google Scholar
- 33.Illingworth MA, Meyer E, Chong WK, Manzur AY, Carr LJ, Younis R, et al. PLA2G6-associated neurodegeneration (PLAN): further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease. Mol Genet Metab. 2014;112:183–9.CrossRefGoogle Scholar
- 41.Shetty A, Gan-Or Z, Ashtiani S, Ruskey JA, van de Warrenburg B, Wassenberg T, et al. CAPN1 mutations: expanding the CAPN1-related phenotype: from hereditary spastic paraparesis to spastic ataxia. Eur J Med Genet. 2018. https://doi.org/10.1016/j.ejmg.2018.12.010 [Epub ahead of print]
- 43.Parodi L, Coarelli G, Stevanin G, Brice A, Durr A. Hereditary ataxias and paraparesias: clinical and genetic update. Curr Opin Neurol. 2018;31:462–71.Google Scholar